<code id='A3F0ECFDDB'></code><style id='A3F0ECFDDB'></style>
    • <acronym id='A3F0ECFDDB'></acronym>
      <center id='A3F0ECFDDB'><center id='A3F0ECFDDB'><tfoot id='A3F0ECFDDB'></tfoot></center><abbr id='A3F0ECFDDB'><dir id='A3F0ECFDDB'><tfoot id='A3F0ECFDDB'></tfoot><noframes id='A3F0ECFDDB'>

    • <optgroup id='A3F0ECFDDB'><strike id='A3F0ECFDDB'><sup id='A3F0ECFDDB'></sup></strike><code id='A3F0ECFDDB'></code></optgroup>
        1. <b id='A3F0ECFDDB'><label id='A3F0ECFDDB'><select id='A3F0ECFDDB'><dt id='A3F0ECFDDB'><span id='A3F0ECFDDB'></span></dt></select></label></b><u id='A3F0ECFDDB'></u>
          <i id='A3F0ECFDDB'><strike id='A3F0ECFDDB'><tt id='A3F0ECFDDB'><pre id='A3F0ECFDDB'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:explore    - browse:2
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          entertainment